Source: BioSpace

Cidara: Cidara Therapeutics Added to Russell 3000 Index

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutiona

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Jeffrey Stein's photo - President & CEO of Cidara

President & CEO

Jeffrey Stein

CEO Approval Rating


Cidara develops and commercializes novel anti-infectives and immunotherapies for the treatment of fungal infections. Read more